Scilex Holding Company Business Acquisition, Transaction Costs
Scilex Holding Company (SCLX) had Business Acquisition, Transaction Costs of $8.15 million as of 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Notes
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2022-11-04
- 2022-09-30: Business Acquisition, Transaction Costs $8.15M.
- 2022-06-30: Business Acquisition, Transaction Costs $8.15M.
- 2022-03-31: Business Acquisition, Transaction Costs $8.15M.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2022-09-30 | $8.15M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $8.15M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $8.15M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |